418
Курс лекций по паллиативной медицине
4. Miravitlles M., Soler-Cataluna J.J., Calle M. et al. Spanish COPD
Guidelines (GesEPOC): pharmacological treatment of stable
COPD. Spanish Society of Pulmonologyand Thoracic Surgery //
Arch. Bronconeumol. 2012. Vol. 48. № 7. P. 247–257.
5. Kim V., Han M.K., Vance G.B. et al. The chronic bronchitic
phenotype of COPD: an analysis of the COPDGene Study //
Chest. 2011. Vol. 140. № 3. P. 626–633.
6. Nishimura M., Makita H., Nagai K. et al. Annual change in
pulmonary function and clinical phenotype in chronic obstructive
pulmonary disease // Am. J. Respir. Crit. CareMed. 2012. Vol. 185.
№ 1. P. 44–52
7. Hurst J.R., Vestbo J., AnzuetoA. et al. Susceptibility to exacerbation
in chronic obstructive pulmonary disease // N. Engl. J. Med. 2010.
Vol. 363. № 12. P. 1128–1138.
8. Leigh R., Pizzichini M.M., Morris M.M. et al. Stable COPD:
predictingbenefitfromhigh-doseinhaledcorticosteroidtreatment//
Eur. Respir. J. 2006. Vol. 27. № 5.P. 964–971.
9. Lee J.H., LeeY.K.,KimE.K. et al. Responses to inhaled long-acting
beta-agonist and corticosteroid according to COPD subtype //
Respir. Med. 2010. Vol. 104. № 4.P. 542–549.
10. Rabe K.F. Update on roflumilast, a phosphodiesterase 4 inhibitor
for the treatment of chronic obstructive pulmonary disease //
Br. J. Pharmacol. 2011. Vol. 163. № 1.P. 53–67.
11. Aysanov Z.R., Chernyak A.V., Kalmanova E.N. Spirometry for
diagnosis and therapeutic efficacy evaluation in chronic obstructive
pulmonary disease in primary care. Pulmonology. 2014;(5):101-
110. (In Russ.)
12. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С.,
Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шме-
лев Е.И. Российское респираторное общество. Федеральные
клинические рекомендации по диагностике и лечению хро-
нической обструктивной болезни легких // Пульмонология,
2014; 3: 15–54. 12. Tashkin D.P. Long-acting anticholinergic
use in chronic obstructive pulmonary disease: efficacy and safety.
CurrOpinPulmMed, 2010, 16: 97-105.
13. Arievich H., Overend T., Renard D., et al. Glycopyrronium, an
inhaled long-acting muscarinic antagonist: a dose-ranging study in
patients with COPD. BMC Pulm Med, 2012, 12: 74.
